Peptidream

PeptiDream is a privately-held Tokyo-based biopharmaceutical company founded on July 3rd, 2006 based on novel peptide expression and platform selection technologies developed by Professor and company cofounder Hiroaki Suga at the University of Tokyo, and previously at the State University of New York (SUNY) at Buffalo. PeptiDream holds the exclusive licenses to the worldwide patent rights to all of Professor Suga's technology. PeptiDream's offices and research labs, and staff of roughly 40, are located within a state-of-the-art commercial research center on the University of Tokyo's Komaba Research Campus.

PeptiDream's proprietary PDPS (Peptide Discovery Platform System) is a highly versatile peptide generation and selection platform consisting of three core technologies; Flexizyme technology, translation, cyclization, and peptide modifying technologies, and PD display technology. The combination of these technologies allows PeptiDream to engineer peptide libraries consisting of trillions of unique macrocyclic and helical nonstandard peptides that exhibit improved physical, chemical, and pharmacological properties compared to conventional peptides. With this system, hundreds of highly potent nonstandard peptides can be identified against any target in weeks, covering a wide variety of peptide classes and structures. PeptiDream scientists can then screen hundreds of hits a week for the desired target binding, selectivity, and activity by independently expressing each peptide using PeptiDream's PDTS translation system, without the bottleneck of expensive and time consuming chemical synthesis, significantly increasing the speed of lead identification. Leads can then be chemically synthesized and purified for downstream validation and further development.